Under BXR treatment, a reduced frequency of cells with these gut-homing receptors was observed in the blood of CTCL patients regarding memory T cells (mean off: 1.9%; on: 0.6%) and B cells (mean off: 5.7%, on: 4%).<h4>Conclusion</h4>BXR via RXRs directly targets B and T lymphocytes, inducing retinoid target gene expression, including gut-homing receptors. This evidence concerns the gene NR1I2 and primary cutaneous T-cell non-Hodgkin lymphoma.